US Congress Senate Bill 483 (Prior Session Legislation)

---

Completed Legislative Action
Spectrum: Moderate Partisan Bill (Republican 4-1)
Status: Passed on April 19 2016 - 100% progression
Action: 2016-04-19 - Became Public Law No: 114-145. (TXT | PDF)
Text: Latest bill text (Enrolled) [PDF]

Ensuring Patient Access and Effective Drug Enforcement Act of 2016 Amends the Controlled Substances Act to define: (1) "factors as may be relevant to and consistent with the public health and safety," for purposes of the Attorney General's determination of whether registering an applicant to manufacture or distribute a controlled substance in schedule I or II is in the public interest, as factors that are relevant to and consistent with the findings of such Act; and (2) "imminent danger to the public health or safety," for purposes of the suspension of such a registration, to mean that in the absence of an immediate suspension order, controlled substances will continue to be distributed or dispensed by a registrant who knows or should know, through fulfilling the obligations of the registrant under such Act, that the dispensing is outside the usual course of professional practice, that the distribution or dispensing poses a present or foreseeable risk of adverse health consequences or death due to the abuse or misuse of the controlled substances, or that the controlled substances will continue to be diverted outside of legitimate distribution channels. Requires an order to show cause as to why such a registration should not be denied, revoked, or suspended to: (1) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated; (2) direct the applicant or registrant to appear before the Attorney General at a specific place and time within 30 days after receipt of the order; and (3) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before such appearance. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modifications to such plan. Makes such requirements inapplicable to the issuance of an immediate suspension order. Directs the Department of Health and Human Services, acting through the Food and Drug Administration and the Centers for Disease Control and Prevention, to submit a report identifying: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

Ensuring Patient Access and Effective Drug Enforcement Act of 2016

Sen. Orrin Hatch [R-UT]	Sen. Sheldon Whitehouse [D-RI]	Sen. Marco Rubio [R-FL]	Sen. David Vitter [R-LA]
Sen. Bill Cassidy [R-LA]

Date	Chamber	Action
2016-04-19	House	Became Public Law No: 114-145. (TXT | PDF)
2016-04-19	House	Signed by President.
2016-04-14	House	Presented to President.
2016-04-12	House	Motion to reconsider laid on the table Agreed to without objection.
2016-04-12	House	On passage Passed without objection. (text: CR H1618-1619)
2016-04-12	House	Considered by unanimous consent. (consideration: CR H1618-1619)
2016-04-12	House	Mr. Lance asked unanimous consent to take from the Speaker's table and consider.
2016-03-21	House	Held at the desk.
2016-03-21	House	Received in the House.
2016-03-18	Senate	Message on Senate action sent to the House.
2016-03-17	Senate	Passed Senate with an amendment by Unanimous Consent. (consideration: CR S1605-1606; text as passed Senate: CR S1605-1606)
2016-02-11	Senate	Placed on Senate Legislative Calendar under General Orders. Calendar No. 368.
2016-02-11	Senate	Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
2016-02-11	Senate	Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
2015-02-12	Senate	Read twice and referred to the Committee on the Judiciary.

HB471 (Related) 2015-04-22 - Received in the Senate and Read twice and referred to the Committee on the Judiciary.

Type	Source
Summary	https://www.congress.gov/bill/114th-congress/senate-bill/483/all-info
Text	https://www.congress.gov/114/bills/s483/BILLS-114s483is.pdf
Text	https://www.congress.gov/114/bills/s483/BILLS-114s483rs.pdf
Text	https://www.congress.gov/114/bills/s483/BILLS-114s483es.pdf
Text	https://www.congress.gov/114/bills/s483/BILLS-114s483enr.pdf